L

Lineage Cell Therapeutics Inc
TASE:LCTX

Watchlist Manager
Lineage Cell Therapeutics Inc
TASE:LCTX
Watchlist
Price: 227.9 ILS -14.13% Market Closed
Market Cap: 114.6m ILS
Have any thoughts about
Lineage Cell Therapeutics Inc?
Write Note

Intrinsic Value

LCTX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one LCTX stock under the Base Case scenario is 158.29 ILS. Compared to the current market price of 227.9 ILS, Lineage Cell Therapeutics Inc is Overvalued by 31%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

LCTX Intrinsic Value
158.29 ILS
Overvaluation 31%
Intrinsic Value
Price
L
Worst Case
Base Case
Best Case

Valuation Backtest
Lineage Cell Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for LCTX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about LCTX?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Lineage Cell Therapeutics Inc

Provide an overview of the primary business activities
of Lineage Cell Therapeutics Inc.

What unique competitive advantages
does Lineage Cell Therapeutics Inc hold over its rivals?

What risks and challenges
does Lineage Cell Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Lineage Cell Therapeutics Inc recently?

Summarize the latest earnings call
of Lineage Cell Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Lineage Cell Therapeutics Inc.

Provide P/S
for Lineage Cell Therapeutics Inc.

Provide P/E
for Lineage Cell Therapeutics Inc.

Provide P/OCF
for Lineage Cell Therapeutics Inc.

Provide P/FCFE
for Lineage Cell Therapeutics Inc.

Provide P/B
for Lineage Cell Therapeutics Inc.

Provide EV/S
for Lineage Cell Therapeutics Inc.

Provide EV/GP
for Lineage Cell Therapeutics Inc.

Provide EV/EBITDA
for Lineage Cell Therapeutics Inc.

Provide EV/EBIT
for Lineage Cell Therapeutics Inc.

Provide EV/OCF
for Lineage Cell Therapeutics Inc.

Provide EV/FCFF
for Lineage Cell Therapeutics Inc.

Provide EV/IC
for Lineage Cell Therapeutics Inc.

Show me price targets
for Lineage Cell Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Lineage Cell Therapeutics Inc?

How accurate were the past Revenue estimates
for Lineage Cell Therapeutics Inc?

What are the Net Income projections
for Lineage Cell Therapeutics Inc?

How accurate were the past Net Income estimates
for Lineage Cell Therapeutics Inc?

What are the EPS projections
for Lineage Cell Therapeutics Inc?

How accurate were the past EPS estimates
for Lineage Cell Therapeutics Inc?

What are the EBIT projections
for Lineage Cell Therapeutics Inc?

How accurate were the past EBIT estimates
for Lineage Cell Therapeutics Inc?

Compare the revenue forecasts
for Lineage Cell Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Lineage Cell Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Lineage Cell Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Lineage Cell Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Lineage Cell Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Lineage Cell Therapeutics Inc with its peers.

Analyze the financial leverage
of Lineage Cell Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Lineage Cell Therapeutics Inc.

Provide ROE
for Lineage Cell Therapeutics Inc.

Provide ROA
for Lineage Cell Therapeutics Inc.

Provide ROIC
for Lineage Cell Therapeutics Inc.

Provide ROCE
for Lineage Cell Therapeutics Inc.

Provide Gross Margin
for Lineage Cell Therapeutics Inc.

Provide Operating Margin
for Lineage Cell Therapeutics Inc.

Provide Net Margin
for Lineage Cell Therapeutics Inc.

Provide FCF Margin
for Lineage Cell Therapeutics Inc.

Show all solvency ratios
for Lineage Cell Therapeutics Inc.

Provide D/E Ratio
for Lineage Cell Therapeutics Inc.

Provide D/A Ratio
for Lineage Cell Therapeutics Inc.

Provide Interest Coverage Ratio
for Lineage Cell Therapeutics Inc.

Provide Altman Z-Score Ratio
for Lineage Cell Therapeutics Inc.

Provide Quick Ratio
for Lineage Cell Therapeutics Inc.

Provide Current Ratio
for Lineage Cell Therapeutics Inc.

Provide Cash Ratio
for Lineage Cell Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Lineage Cell Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Lineage Cell Therapeutics Inc?

What is the current Free Cash Flow
of Lineage Cell Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Lineage Cell Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Lineage Cell Therapeutics Inc

Current Assets 40.4m
Cash & Short-Term Investments 38.5m
Receivables 235k
Other Current Assets 1.7m
Non-Current Assets 62.4m
PP&E 4.6m
Intangibles 57.2m
Other Non-Current Assets 598k
Current Liabilities 15.3m
Accounts Payable 2.4m
Accrued Liabilities 3.7m
Other Current Liabilities 9.2m
Non-Current Liabilities 19.2m
Long-Term Debt 68k
Other Non-Current Liabilities 19.2m
Efficiency

Earnings Waterfall
Lineage Cell Therapeutics Inc

Revenue
6.2m USD
Cost of Revenue
-568k USD
Gross Profit
5.6m USD
Operating Expenses
-31.2m USD
Operating Income
-25.6m USD
Other Expenses
1.4m USD
Net Income
-24.2m USD

Free Cash Flow Analysis
Lineage Cell Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

LCTX Profitability Score
Profitability Due Diligence

Lineage Cell Therapeutics Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
Exceptional Revenue Growth Forecast
Declining ROIC
26/100
Profitability
Score

Lineage Cell Therapeutics Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

LCTX Solvency Score
Solvency Due Diligence

Lineage Cell Therapeutics Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Long-Term Solvency
Short-Term Solvency
50/100
Solvency
Score

Lineage Cell Therapeutics Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

LCTX Price Targets Summary
Lineage Cell Therapeutics Inc

Wall Street analysts forecast LCTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LCTX is 1 786.94 ILS with a low forecast of 1 415.54 ILS and a high forecast of 2 575.29 ILS.

Lowest
Price Target
1 415.54 ILS
521% Upside
Average
Price Target
1 786.94 ILS
684% Upside
Highest
Price Target
2 575.29 ILS
1 030% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for LCTX?

Click here to dive deeper.

Dividends

Lineage Cell Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for LCTX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

LCTX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Lineage Cell Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

114.6m ILS

Dividend Yield

0%

Description

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company is headquartered in Carlsbad, California and currently employs 57 full-time employees. The firm is engaged in developing cell therapies for unmet medical needs. The company is focused on developing therapies for degenerative retinal diseases, neurological conditions associated with demyelination and aiding the body in detecting and combating cancer. Specifically, it is testing therapies to treat dry age-related macular degeneration, spinal cord injuries and non-small cell lung cancer. The firm has three allogeneic cell therapy programs: OpRegen, OPC1 and VAC2. OpRegen is a retinal pigment epithelium cell replacement therapy being developed for the treatment of advanced dry age-related macular degeneration (AMD) with geographic atrophy. OPC1 is an oligodendrocyte progenitor cell therapy that is being developed for acute spinal cord injuries (SCI). VAC2 is an allogeneic cancer immunotherapy of antigen-presenting dendritic cells that is being developed for non-small cell lung cancer.

Contact

CALIFORNIA
Carlsbad
2173 Salk Ave Ste 200
+15105213390.0
lineagecell.com

IPO

1992-03-05

Employees

57

Officers

CEO, President & Director
Mr. Brian M. Culley M.A., M.B.A.
CFO & Principal Financial and Accounting Officer
Ms. Jill Ann Howe
General Counsel & Company Secretary
Mr. George A. Samuel III, J.D.
Director of Investor Relations
Ioana C. Hone
Vice President of Corporate Development
Dr. Charlotte Hubbert Ph.D.
Consultant
Ms. Brandi L. Roberts CPA, M.B.A.
Show More
President & CEO of OncoCyte Corporation
Mr. William Annett MBA
Chief Executive Officer of Cell Cure Neurosciences
Dr. Rami Skaliter Ph.D.
Senior Director of Finance & Controller
Ms. Alexandra Hernandez
Vice President of Regulatory Affairs & Quality Control
Dr. Harold D. Waitz
Show Less

See Also

Discover More
What is the Intrinsic Value of one LCTX stock?

The intrinsic value of one LCTX stock under the Base Case scenario is 158.29 ILS.

Is LCTX stock undervalued or overvalued?

Compared to the current market price of 227.9 ILS, Lineage Cell Therapeutics Inc is Overvalued by 31%.

Back to Top